Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Inovio
Inovio
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
You need to be a subscriber to read this article.
Click here
to find out more.
Pharmaceutical
Zika outbreak gives rise to global fears
Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Drug Delivery
Inovio to buy needle-free injection technology from Bioject Medical Technologies for US$5.5m
Non-invasive integrated injection and electroporation device could enhance mass immunisation against infectious diseases
Research & Development
AstraZeneca signs third cancer deal in seven days
MedImmune enters into cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
Research & Development
Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania join forces to tackle influenza and antibiotic-resistant bacteria
The project is awarded US$12.2m by US Defense Advanced Research Projects Agency (DARPA)
Research & Development
Inovio Pharmaceuticals continues building senior team with appointment of VP of Quality
Also makes three promotions in Legal, Clinical and Investor Relations
Drug Delivery
Inovio and US army receive US$3.5m grant
To continue development of a mass vaccination device using electroporation technology
Research & Development
PATH Malaria Vaccine Initiative and Inovio to accelerate malaria vaccine development
Follow-on agreement will lead to clinical trials
Subscribe now